The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17β-estradiol and 0.150 mg Desogestrel for 21 days, followed by 0.030 mg Desogestrel only for 7 days

Contraception

Volumn 54, Issue 6, 1996, Pages 333-338

  Csemiczky, G ^a   Dieben, T ^b   Coeling Bennink, H J ^b   Landgren, Britt Marie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NV ORGANON   (Netherlands)

Author keywords

bleeding; desogestrel; estradiol; oral contraception; ovarian function

Indexed keywords

DESOGESTREL; ESTRADIOL;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; MENSTRUATION; NORMAL HUMAN; ORAL CONTRACEPTION; OVARY CYCLE; OVARY FOLLICLE;

BIOLOGY; CLINICAL RESEARCH; COMPARATIVE STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, PROGESTIN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE METHODS; DESOGESTREL--PHARMACODYNAMICS; ENDOCRINE SYSTEM; ESTRADIOL--PHARMACODYNAMICS; ESTROGENS; FAMILY PLANNING; GENITALIA; GENITALIA, FEMALE; HORMONES; MENSTRUAL CYCLE; MENSTRUATION; ORAL CONTRACEPTIVES; OVARIAN EFFECTS; OVARY; PHYSIOLOGY; REPRODUCTION; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES; UROGENITAL SYSTEM;

ADULT; CONTRACEPTIVES, ORAL; DESOGESTREL; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTRADIOL; FEMALE; HUMANS; OVARY; UTERINE HEMORRHAGE;

EID: 0030560829     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(96)00201-6     Document Type: Article

References (19)

1. 1. Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970;2:203-9.
2. 2. Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980:1092-101.
3. 3. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-92.
4. 4. World Health Organization Collaborative Study of Cardiovascular Disease and Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
5. 5. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1578-82.
6. 6. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silferstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thrombosis Haemostasis 1989;61: 65-9.
7. 7. Toy JL, Davies JA, Hancock KW, McNicol GP. The comparative effects of a synthetic and a "natural" oestrogen on the haemostatic mechanism in patients with primary amenorrhoea. Br J Obst Gynaecol 1978;85:359-62.
8. 8. Åstedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17β-oestradiol. Br J Obst Gynaecol 1979;86:732-36.
9. 9. Serup J, Bostofte E, Larsen S, Westergaard J. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. Acta Obstet Gynecol Scand 1981;60:203-6.
10. 10. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Warram J. The metabolism of estradiol; Oral compared to intravenous administration. J Steroid Biochem 1985; 23:1065-70.
11. 11. Longcope C, Williams KIH. The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone. J Clin Endocrinol Metab 1974;38:602-7.
12. 12. Landgren B-M, Undén A-L, Diczfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. Acta Endocrinol 1980;94:89-98.
13. 13. Wang E, Shi S, Cekan S-Z, Landgren B-M, Diczfalusy E. Hormonal consequences of "missing the pill." Contraception 1982;26:545-66.
14. 14. Landgren B-M, Diczfaluzy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Contraception 1984;29: 437-46.
15. 15. Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic study of the ovarian suppressive activity of low-dose triphasic oral contraceptives during correct and incorrect pill intake. Am J Obstet Gynecol 1989;161: 1159-62.
16. 16. Killick SR. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. Fertil Steril 1989; 52:580-2.
17. 17. Van der Spuy ZM, Sohnius U, Pienaar CA, Schall R. Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users. Contraception 1990;42:597-609.
18. 18. Landgren B-M, Csemiczky G. Missing the pill. Contraception 1991;43:151-61.
19. 19. Wenzl R, Coeling Bennink H, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17β-estradiol. Fertil Steril 1993;60:616-9.